Community Health Media

How is the rapidly changing treatment landscape reshaping second-line ER-positive, HER2-negative metastatic breast cancer care?

In this Special CHM Conversation, Dr. Seth Wander and Dr. Paolo Tarantino discuss the growing number of endocrine therapy options and how clinicians can navigate increasingly complex treatment decisions.

They explore what the newly approved combination of imlunestrant plus abemaciclib means for patients with ESR1 mutations, how ctDNA and molecular profiling guide treatment selection, and why sequencing next-generation endocrine therapies remains an open question as new options emerge.

Topics discussed:

• EMBER-3 and imlunestrant plus abemaciclib
• Treatment options for ESR1-mutated disease
• Single-agent vs combination endocrine therapy
• ctDNA and molecular profiling
• Biomarker-driven treatment selection
• Balancing efficacy and tolerability
• SERENA-6 and molecular progression
• Sequencing next-generation endocrine therapies
• Oral SERDs in the adjuvant and first-line settings
• Emerging doublet and triplet strategies

▶️ Watch this Special CHM Conversation for expert perspectives on navigating the evolving second-line treatment landscape in ER-positive, HER2-negative metastatic breast cancer.

#SethWander #PaoloTarantino #CHMConversations #ESR1 #EMBER3 #EndocrineTherapy #OralSERD #MetastaticBreastCancer #BreastCancer #CommunityHealthMedia

–

Thanks for watching!

Our podcasts are also available on:

• Spotify - https://spotf.fi/chm-podcast

• Amazon Music - https://amazn.so/chm-podcast

• Apple Podcast - https://podcasts.apple.com/us/podcast/community-health-media/id1837428248

• Castbox - https://castbox.fm/vh/6735434

• Goodpods - https://goodpods.com/profile/chm-111066

• iHeartRadio - https://iheart.com/podcast/291542082

• Pocket Casts - https://pca.st/3ncdh11o

–

Community Health Media (CHM) is your full service healthcare communications partner, combining our production expertise with targeted multi-channel campaigns. We connect companies and healthcare brands with key opinion leaders, patients, and consumers through compelling content and live experiences.

We’re an integrated marketing company that produces world-class content and curated peer to peer live experiences.

We specialize in:

• Peer to peer interviews, panels & round-tables
• Curated live events & conferences
• Professional in-depth content & research updates
• Interactive learning modules & webinars
• Live & on-demand webcasts & podcasts

Learn more about us here - https://communityhealth.media

How should clinicians navigate the growing number of treatment options for ESR1-mutated metastatic breast cancer?

Dr. Jason Mouabbi and Dr. Erika Hamilton discuss the evolving treatment landscape for hormone receptor-positive, HER2-negative metastatic breast cancer, with a focus on ESR1 mutations, molecular testing, PROTACs, oral SERDs, and treatment sequencing.

They explore when and how to test for ESR1 mutations, including the role of liquid biopsy and serial testing as resistance emerges. The conversation also examines the differences between a PROTAC and oral SERDs, the clinical data supporting vepdegestrant, and how emerging combination strategies could further reshape endocrine therapy.

Topics discussed:

• Why ESR1 mutations matter in HR-positive/HER2-negative metastatic breast cancer

• When to test and retest for ESR1 mutations

• Tissue NGS vs liquid biopsy for detecting ESR1 mutations

• ESR1 as both a resistance mechanism and a predictive biomarker

• Current treatment options for ESR1-mutated disease

• How PROTACs differ from oral SERDs

• VERITAC-2 and the clinical data supporting vepdegestrant

• Understanding VERITAC-2, EMERALD, and EMBER-3

• Tolerability, GI toxicity, fatigue, and QTc monitoring with vepdegestrant

• Selecting among endocrine monotherapy options

• Retesting ESR1 after progression on an oral SERD

• Sequencing a PROTAC after prior oral SERD therapy

• Imlunestrant plus abemaciclib and emerging combination strategies

• SERENA-6 and switching therapy at molecular progression

• Molecular progression vs radiologic progression

• The future role of PROTAC and CDK4/6 inhibitor combinations

• Why endocrine monotherapy still has an important role

• Preserving endocrine therapy before transitioning to antibody-drug conjugates

• Reconsidering endocrine therapy after treatment with an ADC

• The growing importance of genomic profiling and personalized treatment sequencing

▶️ Watch the full CHM Conversation for expert perspectives on ESR1 testing, endocrine resistance, treatment selection, and the evolving role of oral SERDs and PROTACs in metastatic breast cancer.

#JasonMouabbi #ErikaHamilton #CHMConversations #BreastCancer #MetastaticBreastCancer #ESR1 #HRPositiveBreastCancer #HER2Negative #Vepdegestrant #OralSERD #PROTAC #CommunityHealthMedia

–

Thanks for watching!

Our podcasts are also available on:

• Spotify - https://spotf.fi/chm-podcast

• Amazon Music - https://amazn.so/chm-podcast

• Apple Podcast - https://podcasts.apple.com/us/podcast/community-health-media/id1837428248

• Castbox - https://castbox.fm/vh/6735434

• Goodpods - https://goodpods.com/profile/chm-111066

• iHeartRadio - https://iheart.com/podcast/291542082

• Pocket Casts - https://pca.st/3ncdh11o

–

Community Health Media (CHM) is your full service healthcare communications partner, combining our production expertise with targeted multi-channel campaigns. We connect companies and healthcare brands with key opinion leaders, patients, and consumers through compelling content and live experiences.

We’re an integrated marketing company that produces world-class content and curated peer to peer live experiences.

We specialize in:

• Peer to peer interviews, panels & round-tables

• Curated live events & conferences

• Professional in-depth content & research updates

• Interactive learning modules & webinars

• Live & on-demand webcasts & podcasts

Learn more about us here - https://communityhealth.media

How is T-DXd reshaping the treatment pathway for HER2-positive breast cancer?

Drs. Paolo Tarantino and Seth Wander discuss the rapidly evolving role of trastuzumab deruxtecan (T-DXd) across metastatic and early-stage HER2-positive breast cancer.

From the first-line DESTINY-Breast09 data to the neoadjuvant DESTINY-Breast11 and adjuvant DESTINY-Breast05 data, they explore the new opportunities and clinical questions around treatment selection, maintenance, toxicity management, and personalization.

Topics discussed:

• How DESTINY-Breast09 is changing first-line treatment for metastatic HER2-positive breast cancer

• T-DXd plus pertuzumab compared with the long-standing CLEOPATRA approach

• Why earlier use of T-DXd may improve disease control

• HER2 heterogeneity and the potential impact of T-DXd on CNS progression

• Selecting patients for first-line T-DXd plus pertuzumab

• Complete response, deep partial response, and time to maximal response

• When and how to consider transitioning from T-DXd to maintenance therapy

• PATINA and the role of palbociclib in ER-positive/HER2-positive maintenance

• HER2CLIMB-05 and adding tucatinib to trastuzumab and pertuzumab maintenance

• Personalizing maintenance according to hormone receptor status

• Treatment considerations after progression on first-line T-DXd

• PIK3CA mutations and outcomes with THP vs T-DXd plus pertuzumab

• Managing T-DXd-associated fatigue, nausea, cytopenias, alopecia, and ILD/pneumonitis

• Practical approaches to ILD screening, monitoring, treatment, and rechallenge

• DESTINY-Breast11 and incorporating T-DXd into neoadjuvant treatment

• DESTINY-Breast05 and T-DXd for residual disease after neoadjuvant therapy

• Treatment decisions when residual disease remains after neoadjuvant T-DXd

• The evolving role of CT monitoring in early-stage T-DXd treatment

• Future personalization using MRD, ctDNA, targeted therapies, and treatment escalation or de-escalation

▶️ Watch the full CHM Conversation for expert perspectives on integrating T-DXd across the evolving HER2-positive breast cancer treatment landscape.

#PaoloTarantino #SethWander #CHMConversations #HER2PositiveBreastCancer #BreastCancer #TDXd #TrastuzumabDeruxtecan #DESTINYBreast09 #DESTINYBreast11 #DESTINYBreast05 #CommunityHealthMedia

–

Thanks for watching!

Our podcasts are also available on:

• Spotify - https://spotf.fi/chm-podcast

• Amazon Music - https://amazn.so/chm-podcast

• Apple Podcast - https://podcasts.apple.com/us/podcast/community-health-media/id1837428248

• Castbox - https://castbox.fm/vh/6735434

• Goodpods - https://goodpods.com/profile/chm-111066

• iHeartRadio - https://iheart.com/podcast/291542082

• Pocket Casts - https://pca.st/3ncdh11o

–

Community Health Media (CHM) is your full service healthcare communications partner, combining our production expertise with targeted multi-channel campaigns. We connect companies and healthcare brands with key opinion leaders, patients, and consumers through compelling content and live experiences.

We’re an integrated marketing company that produces world-class content and curated peer to peer live experiences.

We specialize in:

• Peer to peer interviews, panels & round-tables

• Curated live events & conferences

• Professional in-depth content & research updates

• Interactive learning modules & webinars

• Live & on-demand webcasts & podcasts

Learn more about us here - https://communityhealth.media

How is T-DXd changing the treatment landscape for HER2-positive breast cancer?

Drs. Ruta Rao and Irene Kang discuss the evolving role of trastuzumab deruxtecan (T-DXd) across HER2-positive breast cancer, from first-line metastatic disease to neoadjuvant and adjuvant treatment.

They examine data from DESTINY-Breast09, DESTINY-Breast05, and DESTINY-Breast11, along with emerging maintenance strategies from PATINA and HER2CLIMB-05. The conversation also explores how these findings are influencing treatment selection, duration, sequencing, toxicity management, and individualized patient care.

Topics discussed:

• How DESTINY-Breast09 is changing first-line treatment for metastatic HER2-positive breast cancer
• T-DXd plus pertuzumab versus the traditional THP approach
• Complete response, deep partial response, and how long to continue T-DXd plus pertuzumab
• When THP followed by maintenance therapy may still be considered
• Managing T-DXd-associated nausea, ILD/pneumonitis, and fatigue
• Screening, monitoring, and rechallenge considerations for ILD
• PATINA and HER2CLIMB-05 maintenance strategies
• How first-line T-DXd may affect subsequent treatment sequencing
• DESTINY-Breast05 and the role of adjuvant T-DXd in patients with residual disease
• DESTINY-Breast11 and incorporating T-DXd into neoadjuvant therapy
• Selecting patients for neoadjuvant versus adjuvant T-DXd
• Treatment considerations when residual disease remains after neoadjuvant T-DXd
• The potential impact of T-DXd on CNS recurrence and future HER2-positive treatment strategies

▶️ Watch the full CHM Conversation for expert perspectives on translating evolving HER2-positive breast cancer evidence into clinical practice.

#RutaRao #IreneKang #CHMConversations #HER2PositiveBreastCancer #BreastCancer #TDXd #TrastuzumabDeruxtecan #DESTINYBreast09 #DESTINYBreast05 #DESTINYBreast11 #CommunityHealthMedia–

Thanks for watching!

Our podcasts are also available on:

• Spotify - https://spotf.fi/chm-podcast
• Amazon Music - https://amazn.so/chm-podcast
• Apple Podcast - https://podcasts.apple.com/us/podcast...
• Castbox - https://castbox.fm/vh/6735434
• Goodpods - https://goodpods.com/profile/chm-111066
• iHeartRadio - https://iheart.com/podcast/291542082
• Pocket Casts - https://pca.st/3ncdh11o

Community Health Media (CHM) is your full service healthcare communications partner, combining our production expertise with targeted multi-channel campaigns. We connect companies and healthcare brands with key opinion leaders, patients, and consumers through compelling content and live experiences.

We’re an integrated marketing company that produces world-class content and curated peer to peer live experiences.

We specialize in: • Peer to peer interviews, panels & round-tables • Curated live events & conferences • Professional in-depth content & research updates • Interactive learning modules & webinars • Live & on-demand webcasts & podcasts

Learn more about us here - https://communityhealth.media

How is DESTINY-Breast09 changing the first-line treatment landscape for metastatic HER2-positive breast cancer?

Drs. Jason Mouabbi and Neil Iyengar discuss the evolving role of trastuzumab deruxtecan (T-DXd) plus pertuzumab in first-line metastatic HER2-positive breast cancer and how the DESTINY-Breast09 findings are influencing clinical decision-making.

They examine how this approach compares with the long-standing CLEOPATRA regimen, why depth and duration of response matter, and how clinicians can balance efficacy, tolerability, maintenance strategies, and future treatment sequencing when individualizing care.

Topics discussed:

• The HER2-positive metastatic breast cancer landscape before DESTINY-Breast09
• How DESTINY-Breast09 compared T-DXd plus pertuzumab with the CLEOPATRA regimen
• Progression-free survival and the clinical implications of the DB-09 results
• Why using the most active therapies earlier may influence treatment outcomes
• Complete response and the emerging concept of deep partial response
• How treatment duration may affect depth of response with T-DXd plus pertuzumab
• Treatment considerations for patients with PIK3CA-mutated HER2-positive disease
• Managing T-DXd-associated nausea and the role of proactive antiemetic therapy
• ILD monitoring, including kidney function, and rechallenge following grade 1 ILD
• Cardiac monitoring during HER2-directed therapy
• Where PATINA and HER2CLIMB-05 maintenance fit
• Treatment options after progression on first-line T-DXd plus pertuzumab
• The potential role of rebiopsy and changes in HER2 expression after T-DXd
• How prior neoadjuvant or adjuvant T-DXd may influence treatment at metastatic recurrence

▶️ Watch the full CHM Conversation for expert perspectives on applying evolving HER2-positive breast cancer evidence to clinical practice.

#JasonMouabbi #NeilIyengar #CHMConversations #HER2PositiveBreastCancer #MetastaticBreastCancer #BreastCancer #TDXd #TrastuzumabDeruxtecan #DESTINYBreast09 #CommunityHealthMedia

–

Thanks for watching!

Our podcasts are also available on:

• Spotify - https://spotf.fi/chm-podcast

• Amazon Music - https://amazn.so/chm-podcast

• Apple Podcast - https://podcasts.apple.com/us/podcast/community-health-media/id1837428248

• Castbox - https://castbox.fm/vh/6735434

• Goodpods - https://goodpods.com/profile/chm-111066

• iHeartRadio - https://iheart.com/podcast/291542082

• Pocket Casts - https://pca.st/3ncdh11o

–

Community Health Media (CHM) is your full service healthcare communications partner, combining our production expertise with targeted multi-channel campaigns. We connect companies and healthcare brands with key opinion leaders, patients, and consumers through compelling content and live experiences.

We’re an integrated marketing company that produces world-class content and curated peer to peer live experiences.

We specialize in:

• Peer to peer interviews, panels & round-tables

• Curated live events & conferences

• Professional in-depth content & research updates

• Interactive learning modules & webinars

• Live & on-demand webcasts & podcasts

Learn more about us here - https://communityhealth.media

With more targeted therapies available for CLL, how are clinicians navigating the growing number of first-line treatment options?

Drs. Kerry Rogers, William Wierda, and Catherine Coombs discuss the evolving CLL treatment landscape, including fixed-duration versus continuous therapy, BTK- and BCL-2 inhibitor–based approaches, and how disease biology, comorbidities, treatment logistics, and patient preferences can guide treatment selection.

Topics discussed:

• Fixed-duration vs. continuous first-line therapy

• Choosing among BTK inhibitor-based strategies

• Acalabrutinib + venetoclax and venetoclax + obinutuzumab

• Treatment considerations for TP53 mutation and del(17p)

• The emerging investigational role of pirtobrutinib in frontline CLL

• Key testing to inform first-line CLL treatment decisions

• Sequencing therapy and the role of BTK inhibitors after frontline venetoclax-based therapy or chemoimmunotherapy

▶️ Watch the full CHM Conversation and subscribe for more expert discussions translating evolving evidence into clinical practice.

#CHMConversations #KerryRogers #WilliamWierda #CatherineCoombs #CLL #ChronicLymphocyticLeukemia #BTKInhibitors #Venetoclax #Hematology #CommunityHealthMedia

–

Thanks for watching!

Our podcasts are also available on:

• Spotify - https://spotf.fi/chm-podcast

• Amazon Music - https://amazn.so/chm-podcast

• Apple Podcast - https://podcasts.apple.com/us/podcast/community-health-media/id1837428248

• Castbox - https://castbox.fm/vh/6735434

• Goodpods - https://goodpods.com/profile/chm-111066

• iHeartRadio - https://iheart.com/podcast/291542082

• Pocket Casts - https://pca.st/3ncdh11o

–

Community Health Media (CHM) is your full service healthcare communications partner, combining our production expertise with targeted multi-channel campaigns. We connect companies and healthcare brands with key opinion leaders, patients, and consumers through compelling content and live experiences.

We’re an integrated marketing company that produces world-class content and curated peer to peer live experiences.

We specialize in:

• Peer to peer interviews, panels & round-tables

• Curated live events & conferences

• Professional in-depth content & research updates

• Interactive learning modules & webinars

• Live & on-demand webcasts & podcasts

Learn more about us here - https://communityhealth.media

For more than a decade, THP—established by the landmark CLEOPATRA trial— defined the first-line standard for HER2-positive metastatic breast cancer. Now, DESTINY-Breast09 is changing the conversation.

In this CHM Conversation, Dr. Sonya Reid and Dr. Shruti Singh discuss the evolving first-line treatment landscape and how trastuzumab deruxtecan (T-DXd) plus pertuzumab is reshaping clinical decision-making for patients with HER2-positive metastatic breast cancer.

They explore which patients may benefit most from a T-DXd-based approach, how prior T-DXd exposure in early-stage disease could influence treatment at metastatic recurrence, and where THP may still have a role. The conversation also examines practical considerations around toxicity management, maintenance strategies in HER2+ disease, sequencing, and individualized treatment selection.

Topics discussed:

• How CLEOPATRA and THP established the first-line standard

• DESTINY-Breast09 and T-DXd plus pertuzumab

• Treatment considerations for high-risk and HR+/HER2+ disease

• Brain metastases and high visceral disease burden

• How prior neoadjuvant or adjuvant T-DXd may influence treatment

• Managing nausea, fatigue, and ILD with T-DXd

• Dose modifications and maintaining quality of life with T-DXd

• PATINA and HER2CLIMB-05 maintenance approaches

• Treatment sequencing after first-line T-DXd plus pertuzumab

▶️ Watch the full conversation and subscribe to Community Health Media for more expert perspectives on the latest research and evolving approaches in cancer care.

#CHMConversations #SonyaReid #ShrutiSingh #HER2Positive #MetastaticBreastCancer #DESTINYBreast09 #TDXd #TrastuzumabDeruxtecan #BreastCancer #BreastOncology #MedicalOncology #CommunityHealthMedia

–

Thanks for watching!

Our podcasts are also available on:

• Spotify - https://spotf.fi/chm-podcast

• Amazon Music - https://amazn.so/chm-podcast

• Apple Podcast - https://podcasts.apple.com/us/podcast...

• Castbox - https://castbox.fm/vh/6735434

• Goodpods - https://goodpods.com/profile/chm-111066

• iHeartRadio - https://iheart.com/podcast/291542082

• Pocket Casts - https://pca.st/3ncdh11o

–

Community Health Media (CHM) is your full service healthcare communications partner, combining our production expertise with targeted multi-channel campaigns. We connect companies and healthcare brands with key opinion leaders, patients, and consumers through compelling content and live experiences.

We’re an integrated marketing company that produces world-class content and curated peer to peer live experiences.

We specialize in:

• Peer to peer interviews, panels & round-tables

• Curated live events & conferences

• Professional in-depth content & research updates

• Interactive learning modules & webinars

• Live & on-demand webcasts & podcasts

Learn more about us here - https://communityhealth.media

Are antibody-drug conjugates becoming the new first-line standard for metastatic triple-negative breast cancer?

At This Moment in Medicine, hosted by Community Health Media, Dr. Senthil Damodaran reviews the latest data moving ADCs earlier in the treatment landscape for metastatic TNBC.

The presentation focuses on TROPION-Breast02, ASCENT-03, and ASCENT-04, comparing datopotamab deruxtecan (Dato-DXd) and sacituzumab govitecan with chemotherapy, with or without pembrolizumab depending on PD-L1 status. Dr. Damodaran also examines efficacy, toxicity, sequencing, and the practical tradeoffs that may influence which ADC clinicians choose.

Topics discussed:

• Historical first-line treatment of metastatic TNBC
• TROPION-Breast02 and Dato-DXd
• ASCENT-03 and sacituzumab govitecan in PD-L1-negative disease
• ASCENT-04 and sacituzumab govitecan plus pembrolizumab
• Progression-free survival, overall survival, and response rates
• Toxicity differences between Dato-DXd and sacituzumab govitecan
• Stomatitis, ocular toxicity, neutropenia, and supportive care
• Whether TROP-2 expression should guide treatment
• BRCA mutations and where PARP inhibitors may still fit
• CNS activity and intracranial disease
• Choosing between Dato-DXd and sacituzumab govitecan
• ADCs sequencing

The presentation concludes with a practical discussion on one of the biggest questions in TNBC today: If both ADCs are effective, how should clinicians choose between them?

▶️ Watch more from This Moment in Medicine and subscribe to Community Health Media for expert discussions on the latest advances shaping cancer care.

🎧 Subscribe for the latest insights from leading cancer specialists.

#ThisMomentInMedicine #SenthilDamodaran #TripleNegativeBreastCancer #TNBC #ADC #DatoDXd #SacituzumabGovitecan #TROPIONBreast02 #ASCENT03 #ASCENT04 #MedicalOncology #CommunityHealthMedia

–

Thanks for watching!

Our podcasts are also available on:

• Spotify - https://spotf.fi/chm-podcast

• Amazon Music - https://amazn.so/chm-podcast

• Apple Podcast - https://podcasts.apple.com/us/podcast/community-health-media/id1837428248

• Castbox - https://castbox.fm/vh/6735434

• Goodpods - https://goodpods.com/profile/chm-111066

• iHeartRadio - https://iheart.com/podcast/291542082

• Pocket Casts - https://pca.st/3ncdh11o

–

Community Health Media (CHM) is your full service healthcare communications partner, combining our production expertise with targeted multi-channel campaigns. We connect companies and healthcare brands with key opinion leaders, patients, and consumers through compelling content and live experiences.

We’re an integrated marketing company that produces world-class content and curated peer to peer live experiences.

We specialize in:

• Peer to peer interviews, panels & round-tables

• Curated live events & conferences

• Professional in-depth content & research updates

• Interactive learning modules & webinars

• Live & on-demand webcasts & podcasts

Learn more about us here - https://communityhealth.media

How should we approach first-line treatment as the HER2-positive metastatic breast cancer landscape rapidly evolves?

At This Moment in Medicine, hosted by Community Health Media, Dr. Mothaffar Rimawi examines how new data are reshaping a treatment landscape long defined by the CLEOPATRA regimen.

From DESTINY-Breast09 to PATINA and HER2CLIMB-05, Dr. Rimawi explores emerging strategies for deeper HER2 and ER pathway inhibition, the role of T-DXd, and how clinicians might individualize treatment based on disease biology, burden, toxicity, and patient preference.

Topics discussed:

• The evolution of first-line HER2-positive metastatic breast cancer treatment
• CLEOPATRA and the foundation of modern HER2-directed therapy
• PATINA and the addition of palbociclib in HR+/HER2+ disease
• DESTINY-Breast09 and T-DXd plus pertuzumab
• Depth and duration of response with T-DXd
• HER2CLIMB-05 and tucatinib maintenance
• ILD, transaminitis, and other treatment-related toxicities
• Patient-reported outcomes and quality of life
• Selecting treatment based on ER status, CNS disease, disease burden, and molecular profile
• T-DXd duration and the possibility of induction-maintenance strategies
• How PATINA and HER2CLIMB-05 could inform maintenance therapy

The presentation concludes with a panel discussion addressing a critical question for the field: With several highly effective strategies now available, how do we choose the right first-line approach for the right patient?

▶️ Watch more from This Moment in Medicine and subscribe to Community Health Media for expert conversations on the latest advances shaping cancer care.

🎧 Subscribe for the latest insights from leading cancer specialists.

#ThisMomentInMedicine #MothaffarRimawi #HER2Positive #MetastaticBreastCancer #DESTINYBreast09 #TDXd #PATINA #HER2CLIMB05 #BreastOncology #MedicalOncology #CommunityHealthMedia

–

Thanks for watching!

Our podcasts are also available on:

• Spotify - https://spotf.fi/chm-podcast

• Amazon Music - https://amazn.so/chm-podcast

• Apple Podcast - https://podcasts.apple.com/us/podcast/community-health-media/id1837428248

• Castbox - https://castbox.fm/vh/6735434

• Goodpods - https://goodpods.com/profile/chm-111066

• iHeartRadio - https://iheart.com/podcast/291542082

• Pocket Casts - https://pca.st/3ncdh11o

–

Community Health Media (CHM) is your full service healthcare communications partner, combining our production expertise with targeted multi-channel campaigns. We connect companies and healthcare brands with key opinion leaders, patients, and consumers through compelling content and live experiences.

We’re an integrated marketing company that produces world-class content and curated peer to peer live experiences.

We specialize in:

• Peer to peer interviews, panels & round-tables

• Curated live events & conferences

• Professional in-depth content & research updates

• Interactive learning modules & webinars

• Live & on-demand webcasts & podcasts

Learn more about us here - https://communityhealth.media

Where should T-DXd fit in the treatment of high-risk, early-stage HER2-positive breast cancer?

At This Moment in Medicine, hosted by Community Health Media, Dr. Michelina Cairo reviews the latest data from DESTINY-Breast11 and DESTINY-Breast05, examining how trastuzumab deruxtecan (T-DXd) could reshape treatment in both the neoadjuvant and adjuvant settings.

From pathologic complete response and invasive disease-free survival to ILD risk and treatment sequencing, the presentation explores how clinicians might balance efficacy, toxicity, and individual recurrence risk as T-DXd moves into earlier-stage disease.

Topics discussed:

• Current treatment for high-risk HER2-positive early breast cancer
• DESTINY-Breast11 and neoadjuvant T-DXd followed by THP
• Pathologic complete response and residual cancer burden
• DESTINY-Breast05 and T-DXd versus T-DM1
• Invasive disease-free survival and emerging CNS outcomes
• ILD, nausea, cardiac safety, and treatment duration
• Neoadjuvant versus adjuvant use of T-DXd
• Whether THP alone may be sufficient for selected patients
• The potential role of ctDNA
• Where T-DM1 may still fit for residual disease
• Individualizing treatment according to recurrence risk

The presentation concludes with a panel discussion exploring one of the biggest unanswered questions: How much T-DXd is enough—and when should it be used?

▶️ Watch more from This Moment in Medicine and subscribe to Community Health Media for expert conversations on the latest advances shaping cancer care.

🎧 Subscribe for the latest insights from leading cancer specialists.

#ThisMomentInMedicine #MichelinaCairo #BreastCancer #HER2Positive #TDXd #TrastuzumabDeruxtecan #DESTINYBreast11 #DESTINYBreast05 #BreastOncology #MedicalOncology #CommunityHealthMedia

–

Thanks for watching!

Our podcasts are also available on:

• Spotify - https://spotf.fi/chm-podcast

• Amazon Music - https://amazn.so/chm-podcast

• Apple Podcast - https://podcasts.apple.com/us/podcast/community-health-media/id1837428248

• Castbox - https://castbox.fm/vh/6735434

• Goodpods - https://goodpods.com/profile/chm-111066

• iHeartRadio - https://iheart.com/podcast/291542082

• Pocket Casts - https://pca.st/3ncdh11o

–

Community Health Media (CHM) is your full service healthcare communications partner, combining our production expertise with targeted multi-channel campaigns. We connect companies and healthcare brands with key opinion leaders, patients, and consumers through compelling content and live experiences.

We’re an integrated marketing company that produces world-class content and curated peer to peer live experiences.

We specialize in:

• Peer to peer interviews, panels & round-tables

• Curated live events & conferences

• Professional in-depth content & research updates

• Interactive learning modules & webinars

• Live & on-demand webcasts & podcasts

Learn more about us here - https://communityhealth.media